Imidazole derivatives for the treatment of gastrointestinal disorders
AssigneeAstraZeneca AB
InventorsUdo Bauer, Wayne Brailsford, Linda Gustafsson, Tor Svensson, Maria Saxin
Life of this patent
Estimating the term…
Loading patent…
AssigneeAstraZeneca AB
InventorsUdo Bauer, Wayne Brailsford, Linda Gustafsson, Tor Svensson, Maria Saxin
Estimating the term…
The present invention relates to novel imidazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R1, R2, R3 and Y are as defined in the description. For example, R1 may be phenyl, R2 may be dimethylamino, R3 may be alkoxy and Y may be a thioylamino- or methyl eneamino- linked substitutuent containing an aryl group.
A compound of the general formula (I), an enantiomer of the compound, or a pharmaceutically acceptable salt of the compound or the enantiomer,
Dependencies are inferred from the claim text.